Last updated: April 24, 2026
Who supplies esmolol hydrochloride double strength (plastic container)?
Esmolol hydrochloride “double strength” is marketed in the U.S. in premixed injectable formats intended for IV use. In practice, the supplier set is driven by (1) whether the product is labeled as “double strength” on the container/carton and (2) whether it is distributed as a ready-to-use plastic container versus a vial/ampoule.
Which companies list esmolol hydrochloride injection (including double-strength labeling) in plastic container?
Below are the supplier companies that publish or distribute injectable esmolol hydrochloride products in the U.S. under branded or authorized-generic channels, including formats that are supplied in plastic containers (premixed bag/container formats and/or bottle-in-bag presentations, depending on the NDC presentation).
Supplier set (market presence)
| Company |
Product category in market |
Evidence type |
| Hospira, a Pfizer Company |
Branded and authorized-generic supplier history for esmolol injection; multiple presentations including premixed IV formats in containerized systems |
FDA product/labeling trail for esmolol injection and manufacturer listings (referenced via Drugs@FDA/labeling) |
| B. Braun |
Injectable esmolol hydrochloride products distributed in some markets as part of hospital supply chain |
FDA/NDC labeling and/or distributor/manufacturer listings (referenced via Drugs@FDA and label/packaging identifiers) |
| Sagent Pharmaceuticals (now part of Lannett / other consolidations depending on product line) |
Authorized-generic channel presence for esmolol injection |
FDA/NDC labeling and manufacturer listings (referenced via Drugs@FDA) |
| Pfizer / Pfizer Labs supply chain entities |
Branded channel and/or legacy supplier entries |
FDA product/labeling entries (referenced via Drugs@FDA) |
What exact bottle/container configuration qualifies as “plastic container”?
Because “plastic container” can mean different presentation formats (IV bag, bottle-in-bag, or other polymeric secondary containment), supplier selection should follow the NDC presentation text that explicitly states the container format (bag/bottle/container) on the labeling.
For esmolol injection, the decisive filter is the NDC presentation that corresponds to:
- the “double strength” concentration statement, and
- the container label language indicating a plastic container format.
How do suppliers map to NDCs (the actionable procurement approach)?
Procurement teams typically source by NDC presentation. In esmolol’s case, the workflow is:
- Identify the NDC for the “double strength” presentation whose label describes the plastic container format.
- Use the NDC’s labeler/manufacturer field to lock supplier identity.
- Verify that the supplier can deliver the exact presentation size and container format used by the purchasing specification.
This supplier mapping is maintained in U.S. labeling databases (FDA Drugs@FDA). (Source: Drugs@FDA product labeling and NDC listing structures.) [1]
What are the key supplier constraints for this specific drug format?
Esmolol hydrochloride double strength is not a commodity in procurement because hospital supply tends to enforce strict match on:
- Strength wording: “double strength” on the label or equivalent concentration text in the prescribing information.
- Container system: polymer container versus glass vial.
- Packaging: single unit versus multipack.
- Sterility and handling: IV ready-to-use container presentation differs operationally from vial-based preparation.
These constraints affect which manufacturers can supply the exact presentation at scale, and they are the reason supplier lists differ across hospitals even within the same drug name.
What is the practical supplier list for sourcing “esmolol hydrochloride double strength in plastic container”?
Use the following supplier set as the starting point for RFP qualification. These firms have maintained market presence for esmolol hydrochloride injectable products and appear in FDA product labeling/manufacturer trails for esmolol injection presentations:
- Pfizer (Hospira legacy): branded/authorized-generic continuity in injectable esmolol supply channels; label/manufacturer trail present in FDA product records. [1]
- B. Braun: manufacturer/distributor presence in injectable hospital supply chain; appears in FDA labeling/NDC records for esmolol presentations depending on jurisdiction. [1]
- Sagent Pharmaceuticals (legacy authorized-generic supplier): appears as labeler/manufacturer in FDA/NDC records for esmolol injection presentations in the U.S. channel history. [1]
Key Takeaways
- Supplier identity for esmolol hydrochloride “double strength” in a plastic container is governed by the exact NDC presentation that matches both the strength claim and the container format stated on the label.
- The actionable U.S. supplier set begins with Pfizer (Hospira legacy), B. Braun, and Sagent (legacy) as firms with FDA labeling/manufacturer trail presence for esmolol injection presentations. [1]
- Procurement should lock the NDC, then confirm the labeler/manufacturer against FDA’s Drugs@FDA listing for that specific presentation before issuing supply commitments. [1]
FAQs
-
How do I confirm the supplier for “double strength” esmolol in a plastic container?
Match the exact NDC for the “double strength” label presentation and then use the labeler/manufacturer field in FDA’s Drugs@FDA entry tied to that NDC. [1]
-
Why can supplier lists differ even when the drug name is the same?
Esmolol injection can be marketed in multiple presentations, and supply chain allocation depends on the presentation-specific labeling, including container type. [1]
-
Do wholesalers count as suppliers for this use case?
For precision sourcing, treat “supplier” as the labeler/manufacturer associated with the NDC presentation rather than the distributor, since container and strength compliance is tied to the labeled NDC record. [1]
-
What database should be used to validate the manufacturer?
FDA’s Drugs@FDA listing and label records keyed by NDC presentation. [1]
-
What procurement specification should be written to avoid mismatches?
Require NDC, strength wording that corresponds to “double strength,” and the label-stated plastic container presentation. [1]
References
[1] U.S. Food and Drug Administration (FDA). Drugs@FDA: FDA-approved drug products and labeling/NDC-linked information for esmolol hydrochloride injection. https://www.accessdata.fda.gov/scripts/cder/daf/
